Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Karyopharm Therapeutics's change in inventory for the quarter that ended in Mar. 2026 was $0.4 Mil. It means Karyopharm Therapeutics's inventory
declined by $0.4 Mil
from Dec. 2025 to Mar. 2026 .
Karyopharm Therapeutics's change in inventory for the fiscal year that ended in Dec. 2025 was $0.7 Mil. It means Karyopharm Therapeutics's inventory
declined by $0.7 Mil
from Dec. 2024 to Dec. 2025 .
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Karyopharm Therapeutics's Days Inventory for the quarter that ended in Mar. 2026 was 259.06.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Karyopharm Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.35.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Karyopharm Therapeutics's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.11.
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Karyopharm Therapeutics's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Karyopharm Therapeutics Change In Inventory Related Terms
Karyopharm Therapeutics Change In Inventory Historical Data
* Premium members only.
The historical data trend for Karyopharm Therapeutics's Change In Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Karyopharm Therapeutics Change In Inventory Calculation
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Karyopharm Therapeutics (KPTI) has a Change In Inventory of $1.2 Mil as of Mar. 2026. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Karyopharm Therapeutics and its competitors.
Is Karyopharm Therapeutics' Change In Inventory too high?
Karyopharm Therapeutics' current Change In Inventory is $1.2 Mil. Overall, Karyopharm Therapeutics has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Karyopharm Therapeutics' Change In Inventory compare to TNYA and HUMA?
Karyopharm Therapeutics' Change In Inventory of $1.2 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Biotechnology company?
A good Change In Inventory depends on the Biotechnology industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Karyopharm Therapeutics and its competitors. Karyopharm Therapeutics's current Change In Inventory is $1.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Karyopharm Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Karyopharm Therapeutics (KPTI) is currently considered Possible Value Trap. The stock's GF Value™ is $5.80, compared to a current price of $1.96 — trading 66.2% below its estimated fair value. The current Change In Inventory is $1.2 Mil. Karyopharm Therapeutics' overall GF Score™ is 47/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For Karyopharm Therapeutics (KPTI), the current Change In Inventory is $1.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Karyopharm Therapeutics (KPTI) Overvalued in 2026?
Based on GuruFocus' analysis, Karyopharm Therapeutics stock appears to be undervalued.
The current stock price of $1.96 is trading 66.2% below its estimated GF Value™ of $5.80.
GuruFocus considers Karyopharm Therapeutics to be Possible Value Trap.
Key valuation signals for KPTI:
Change In Inventory: $1.2 Mil
GF Value™: $5.80 vs. price of $1.96 (66.2% below fair value)
No single metric tells the full story. See the KPTI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
47GF Score
Get the complete analysis for KPTI
Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KPTI has been successfully added to your 
